Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency

Case Report: Whole exome sequencing identifies... | F1000Research A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency" /> "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency" /> { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/5-2532" }, "headline": "Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T-...", "datePublished": "2016-10-18T15:02:30", "dateModified": "2017-10-02T09:48:00", "author": [ { "@type": "Person", "name": "Geeta Madathil Govindaraj" }, { "@type": "Person", "name": "Shamsudheen Karuthedath Vellarikkal" }, { "@type": "Person", "name": "Rijith Jayarajan" }, { "@type": "Person", "name": "Rowmika Ravi" }, { "@type": "Person", "name": "Ankit Verma" }, { "@type": "Person", "name": "Krishnan Chakkiyar" }, { "@type": "Person", "name": "Machinari Puthenpurayil Jayakrishnan" }, { "@type": "Person", "name": "Riyaz Arakkal" }, { "@type": "Person", "name": "Revathi Raj" }, { "@type": "Person", "name": "Rajeevan Kunnaruvath" }, { "@type": "Person", "name": "Sridhar Sivasubbu" }, { "@type": "Person", "name": "Vinod Scaria" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": "Severe combined immunodeficiency is a large clinically heterogeneous group of disorders caused by a defect in the development of humoral or cellular immune responses. At least 13 genes are known to be involved in the pathophysiology of the disease and the mutation spectrum in SCID has been well documented. Mutations of the recombination-activating genes RAG 1 and RAG 2 are associated with a range of clinical presentations including, severe combined immunodeficiency and autoimmunity. Recently, our understanding of the molecular basis of immune dysfunction in RAG deficiency has improved tremendously with newer insights into the ultrastructure of the RAG complex. In this report, we describe the application of whole exome sequencing for arriving at a molecular diagnosis in a child suffering from B- T- NK+ severe combined immunodeficiency. Apart from making the accurate molecular diagnosis, we also add a genetic variation c.2308G>A p.E770K to the compendium of variations associated with the disease." } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/5-2532", "name": "Case Report: Whole exome sequencing identifies variation c.2308G>A..." } } ] } Home Browse Case Report: Whole exome sequencing identifies variation c.2308G>A... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Govindaraj GM, Karuthedath Vellarikkal S, Jayarajan R et al. Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.12688/f1000research.9473.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Case Report Revised Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] Geeta Madathil Govindaraj 1 * , Shamsudheen Karuthedath Vellarikkal 2,3 * , Rijith Jayarajan 3 , [...] Rowmika Ravi 3 , Ankit Verma 3 , Krishnan Chakkiyar 1 , Machinari Puthenpurayil Jayakrishnan 1 , Riyaz Arakkal 1 , Revathi Raj 4 , Rajeevan Kunnaruvath 5 , Sridhar Sivasubbu 2,3 , Vinod Scaria 2,6 Geeta Madathil Govindaraj 1 * , Shamsudheen Karuthedath Vellarikkal 2,3 * , [...] Rijith Jayarajan 3 , Rowmika Ravi 3 , Ankit Verma 3 , Krishnan Chakkiyar 1 , Machinari Puthenpurayil Jayakrishnan 1 , Riyaz Arakkal 1 , Revathi Raj 4 , Rajeevan Kunnaruvath 5 , Sridhar Sivasubbu 2,3 , Vinod Scaria 2,6 * Equal contributors PUBLISHED 02 Oct 2017 Author details Author details 1 Department of Pediatrics, Institute of Maternal and Child Health, Government Medical College, Kozhikode, India 2 Academy of Scientific and Innovative Research (AcSIR), CSIR-IGIB, Delhi, India 3 Genomics and Molecular Medicine Unit, CSIR Institute of Genomics and Integrative Biology, Delhi, India 4 Apollo Speciality Hospital, Chennai, India 5 Department of Pathology, Government Medical College, Kozhikode, India 6 GN Ramachandran Knowledge Center for Genome Informatics, CSIR Institute of Genomics and Integrative Biology, Delhi, India Geeta Madathil Govindaraj Roles: Writing – Original Draft Preparation Shamsudheen Karuthedath Vellarikkal Roles: Data Curation, Methodology, Validation, Writing – Original Draft Preparation Rijith Jayarajan Roles: Data Curation, Methodology, Validation Rowmika Ravi Roles: Methodology, Validation, Writing – Original Draft Preparation Ankit Verma Roles: Data Curation, Methodology, Validation, Writing – Review & Editing Krishnan Chakkiyar Roles: Investigation Machinari Puthenpurayil Jayakrishnan Roles: Investigation Riyaz Arakkal Roles: Writing – Review & Editing Revathi Raj Roles: Investigation Rajeevan Kunnaruvath Roles: Investigation Sridhar Sivasubbu Roles: Conceptualization, Funding Acquisition, Resources, Writing – Original Draft Preparation, Writing – Review & Editing Vinod Scaria Roles: Conceptualization, Data Curation, Formal Analysis, Resources, Writing – Original Draft Preparation, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Severe combined immunodeficiency is a large clinically heterogeneous group of disorders caused by a defect in the development of humoral or cellular immune responses. At least 13 genes are known to be involved in the pathophysiology of the disease and the mutation spectrum in SCID has been well documented. Mutations of the recombination-activating genes RAG 1 and RAG 2 are associated with a range of clinical presentations including, severe combined immunodeficiency and autoimmunity. Recently, our understanding of the molecular basis of immune dysfunction in RAG deficiency has improved tremendously with newer insights into the ultrastructure of the RAG complex. In this report, we describe the application of whole exome sequencing for arriving at a molecular diagnosis in a child suffering from B- T- NK+ severe combined immunodeficiency. Apart from making the accurate molecular diagnosis, we also add a genetic variation c.2308G>A p.E770K to the compendium of variations associated with the disease. READ ALL READ LESS Keywords Severe Combined Immunodeficiency, B- T- NK+ SCID, Whole Exome Sequencing, RAG1 Corresponding Author(s) Sridhar Sivasubbu ( [email protected] ) Vinod Scaria ( [email protected] ) Close Corresponding authors: Sridhar Sivasubbu, Vinod Scaria Competing interests: No competing interests were disclosed. Grant information: SS and VS acknowledge funding from the Council of Scientific and Industrial Research (CSIR) India through Grant BSC0212. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: © 2017 Govindaraj GM et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Govindaraj GM, Karuthedath Vellarikkal S, Jayarajan R et al. Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.12688/f1000research.9473.2 ) First published: 18 Oct 2016, 5 :2532 ( https://doi.org/10.12688/f1000research.9473.1 ) Latest published: 02 Oct 2017, 5 :2532 ( https://doi.org/10.12688/f1000research.9473.2 ) Revised Amendments from Version 1 This updated version of the manuscript is incorporated with reviewers’ suggestions and more information on clinical findings of patient. A new author, Dr Rajeevan Kunnaruvath, was added to this new version of the manuscript because of his contribution in interpreting the flow cytometry data of the patient. This updated version of the manuscript is incorporated with reviewers’ suggestions and more information on clinical findings of patient. A new author, Dr Rajeevan Kunnaruvath, was added to this new version of the manuscript because of his contribution in interpreting the flow cytometry data of the patient. See the authors' detailed response to the review by Paola Itliani See the authors' detailed response to the review by David K. Buchbinder READ REVIEWER RESPONSES Introduction Severe combined immunodeficiency (SCID) encompasses a constellation of clinically and genetically heterogeneous diseases resulting in defects of the humoral and/or cellular immune defense mechanism 1 . The patients with SCID exhibit recurrent infections with bacteria, virus and fungi. The deficiency of recombination activating gene is associated with T - B - NK + SCID. Recombination of activating gene enzymes plays a significant role in recombination of V(D)J segments 2 . The mutation in recombination activating gene 1 ( RAG1 ) is associated with absence of V(D)J recombination, which in turn produces immature lymphocytes leading to SCID 3 . The accurate molecular diagnosis in SCID enables genetic counselling for disease 4 . So far, arriving at a precise molecular diagnosis has been quite cumbersome, technically challenging and expensive, as over a dozen genes are known to be implicated in the genetic disease, which would require systematic targeted sequencing of each of the gene 5 , 6 . The advent of next generation sequencing, especially whole exome and sometimes whole genome sequencing has significantly enabled the rapid identification of the causative genetic variations in clinical settings 6 . In this report, we describe the application of whole exome sequencing for the accurate molecular diagnosis of a case of T - B - NK+ SCID. Our report also adds a genetic variation c.2308G>A p.E770K in Recombination activating gene 1 ( RAG1 ) to the compendium of variations associated with the disease. Case report Here we report a case of a seven-month-old boy, born out of a third degree consanguineous marriage, with a history of recurrent episodes of pneumonia, acute otitis media, diarrhea and oral thrush since two months of age. The child was pale, emaciated, febrile, and had respiratory distress with lower chest retractions. He was in compensated shock. There was no clubbing, cyanosis or lymphadenopathy. There was no facial dysmorphism, and skin and hair were normal. He weighed 5.4 kg; measured 64 cm in length and head circumference was 39.5 cm; all below the 3rd centile as per WHO Child Growth Standards. Examination of the chest showed evidence of bronchopneumonia while there was no evidence of congenital heart disease or neurological deficits. There was mild hepatomegaly with a liver span of 6.5 cm. The baby was normal in the perinatal and postnatal period. His birth weight was normal (3.04 kg) and was asymptomatic until 2 months of age. There was a history of admission to pediatric intensive care unit (PICU) and artificial ventilation for severe pneumonia at the age of 2 months. He was admitted for 22 days during that episode. The child had gross motor developmental delay and no adverse events following immunization. He had a male sibling who expired at seven months of age due to persistent pneumonia and two unaffected female siblings, apart from a half-brother and half-sister both of whom were asymptomatic ( Figure 1A ). Figure 1. ( a ) Pedigree of the family ( b ) domain mapping of the RAG1 p.E770K on RAG1 protein showing the variation lies on RAG1 domain highlighted with red triangle and ( c ) capillary sequencing of the locus in the proband and family members. The homozygous variation c.2308G>A in the proband is marked with an asterisk. On investigation, the child was found to have hypochromic microcytic anemia, lymphocytopenia, and a normal eosinophil count and platelet count. Liver and renal function tests were normal. The ionized calcium was 0.28mmol/L. Blood culture was positive for Enterobacter species. The child’s mother was HIV ELISA negative and the child had a negative Mantoux test and negative gastric acid AFB stain. His chest X-Ray’s lateral view showed absence of the thymus shadow apart from evidence of bronchopneumonia. A close workup of the immunoglobulin profile revealed hypogammaglobulinemia-IgA 23 mg%, IgG 44 mg% and IgM 26 mg%. IgE was 1 IU/L. The absolute CD3 count was 464 cells/ul (normal range 1,460–5,440 cells/ul), absolute CD19 lymphocyte count was 12 cells/ul (normal 430–3,300 cells/ul) and absolute NK cell count was 1,328 cells/ul (normal 80–340 cells/ul). Flow cytometry suggested absent B and markedly reduced T cell populations suggestive of B- T- NK+ SCID. The child was treated with piperacillin (80mg/kg/dose Q8H), vancomycin (15 mg/kg/dose Q6H), dopamine (10 mic/kg/min), intravenous immunoglobulin (IVIG) and other supportive measures and was put on cotrimoxazole (6 mg/kg/day OD) prophylaxis. He was treated with ganciclovir for CMV infection and for staphylococcal pneumonia. The child was referred for a bone marrow transplant, since SCID is not compatible with life beyond infancy. The patient underwent a matched sibling donor bone marrow transplant at the age of 1 year and 3 months. The conditioning regimen used was Fludarbine 40mg/M2 for 4 days, and Treosulphan 12 gm/M2 for 3 days. GVHD prophylaxis was provided with Methotrexate 10 mg/M2 on days 1, 3 and 6 following transplant, along with Tacrolimus on day 0. Leuconostoc sepsis was treated with intravenous Amoxicillin and Clavulanic acid. Chimerism was assessed using whole blood by fluorescence in situ hybridization (FISH) as the transplant was sex mismatched. At 6 months post- transplant, chimerism was down to 28%, and hence 2 donor lymphocyte infusions were given. The last assessment was done at 1 year by T and B cell markers and serum immunoglobulins, and these were found to be within the normal range. The chilld is now one year three months post-transplant and off all medications including immunosuppressive therapy. The clinical diagnosis of SCID and family history of sibling death prompted us to investigate the molecular genetic correlates of the disease. Since over 13 genes are implicated in SCID and regular molecular testing was not readily available for the genes, we resorted to whole exome sequencing. Methods After obtaining informed consent from the parents, blood was drawn by venipuncture under aseptic precautions. DNA was isolated from whole blood using salting out method 7 . Exome capture was performed on DNA using the Illumina Nextera rapid capture expanded exome kit using standard protocols (Illumina Inc USA). We generated 47.95 million paired end reads and an average on target coverage of over 25x on Illumina HiSeq 2500 (Illumina Inc. USA). Alignment was performed using BWA (v0.7.12-r1039) 8 and Stampy (v1.0.20) 9 and variants were called using Platypus (v0.8.1) 10 . For the prioritisation of variants, we filtered all homozygous variants, further filtered by an allele frequency of <1% in the 1000 Genome and ExAC. Variants in the 13 genes were prioritised and annotated for their deleteriousness using SIFT, Polyphen and Mutation Taster annotations obtained from annovar 11 . Results Whole exome sequencing analysis revealed a homozygous missense variation (c.2308G>A) in exon number 2 of recombination activating gene 1 ( RAG1 ). The variant was predicted to be highly deleterious by SIFT (score 0.000), PolyPhen2 (0.991) and Mutation Taster (1.00). The variation causes an amino acid change p.E770K, which lies on RAG1 domain of the protein ( Figure 1b ). The present variation was not found in the 1000 Genome ( http://browser.1000genomes.org/index.html ), ExAC ( http://exac.broadinstitute.org/ ) or internal control database of over 150 exomes from South East Asian ancestry. Incidentally the mutation was previously reported and analysis suggested a significantly reduced recombination activity 12 . The variation was further confirmed using targeted PCR amplification around the locus and confirmed by capillary sequencing. The variant was found to be heterozygous in both the parents as well as the surviving siblings ( Figure 1c ). The status of the variation could not be ascertained in the sibling who died because no sample was archived and primary immune deficiency was not suspected at the time. Discussion Mutations in recombinase activating gene ( RAG1) cause various degrees of severe combined immunodeficiency syndrome (SCID). RAG1 is involved in the V(D)J recombination 1 , 2 , 13 . The child was suspected to have a primary immune deficiency disorder since he had unusually frequent and severe infections and in addition had lost a male sibling due to similar illness. Further, he was born to third degree consanguineous parents. The early onset of symptoms by 2 months of life with increased susceptibility to both bacterial and fungal infections was a pointer to a T cell defect or a phagocytic defect rather than to an antibody deficiency like X linked agammaglobulinemia, which usually presents by 5 to 6 months of age, when maternal antibodies are on the wane 14 . The immunoglobulin profile showed that there was also a B cell defect. The low absolute lymphocyte counts coupled with radiological evidence of an absent thymus shadow was proof of a T cell defect as well. Thus, a provisional diagnosis of a severe combined immunodeficiency was made even before the flow cytometry results became available and helped confirm the diagnosis. The possibility of Omenn syndrome was not considered since there was no history of a rash and there was no lymphadenopathy or hepatosplenomegaly, nor was there eosinophilia in the peripheral smear. X-linked recessive severe combined Immunodeficiency (SCID) is characterized by an elevated percentage of B cells and the absence of B cells in the child ruled this out. Janus kinase 3 (Jak3) deficiency was also not thought of for the same reason. Adenosine deaminase (ADA) deficient SCID is characterized by bony abnormalities including rib cage defects, which were absent. RAG1 or RAG2 deficiencies are associated with a lack of both B cells and T cells and NK cells are predominant in the circulation 13 , 15 . With this possibility in mind, and with a view to offer genetic counselling to the family, whole exome sequencing was considered. Whole exome sequencing identified a mutation c.2308G>A p.E770K in RAG1 , which was previously reported and shown to significantly reduce recombination activity 12 . We feel that whole exome sequencing can have more extensive application in the management of primary immune deficiency in developing countries like India, and can add to rapidly expanding scientific knowledge in this arena. Ethics approval The whole exome sequencing was approved by the Institutional Ethical Committee of CSIR - Institute of Genomics and Integrative Biology (IHECC proposal number 8). Consent Written informed consent for publication of the patients’ details and/or their images was obtained from the patients/parents of the patient. Data availability All the raw sequencing data are available at the NCBI Sequence Read Archive ( http://www.ncbi.nlm.nih.gov/sra ), accession number SRR4088561. Author contributions GMG, KC, MPJ, RA, RR and RK clinically evaluated and characterized the patient. SKV, RJ, RR and AV performed the whole exome sequencing, computational analysis, data interpretation and validation experiments. SS and VS oversaw all the experiments and data interpretation. VS, SKV, GG and SS contributed towards writing the manuscript. Competing interests No competing interests were disclosed. Grant information SS and VS acknowledge funding from the Council of Scientific and Industrial Research (CSIR) India through Grant BSC0212. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Acknowledgment Authors acknowledge support from the GUaRDIAN consortium. Faculty Opinions recommended References 1. Fischer A: Severe combined immunodeficiencies (SCID). Clin Exp Immunol. 2000; 122 (2): 143–9. PubMed Abstract | Publisher Full Text | Free Full Text 2. Rivera-Munoz P, Malivert L, Derdouch S, et al. : DNA repair and the immune system: From V(D)J recombination to aging lymphocyte. Eur J Immunol. 2007; 37 (S1): S71–82. PubMed Abstract | Publisher Full Text 3. Corneo B, Moshous D, Güngör T, et al. : Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood. 2001; 97 (9): 2772–6. PubMed Abstract | Publisher Full Text 4. Fischer A, Notarangelo LD, Neven B, et al. : Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers. 2015; 1 : 15061. PubMed Abstract | Publisher Full Text 5. Zhang W, Cui H, Wong LJ: Application of next generation sequencing to molecular diagnosis of inherited diseases. Top Curr Chem. 2014; 336 : 19–45. PubMed Abstract | Publisher Full Text 6. Sawyer SL, Hartley T, Dyment DA, et al. : Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care. Clin Genet. 2016; 89 (3): 275–84. PubMed Abstract | Publisher Full Text | Free Full Text 7. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16 (3): 1215. PubMed Abstract | Publisher Full Text | Free Full Text 8. Li H, Durbin R: Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25 (14): 1754–60. PubMed Abstract | Publisher Full Text | Free Full Text 9. Lunter G, Goodson M: Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. Genome Res. 2011; 21 (6): 936–9. PubMed Abstract | Publisher Full Text | Free Full Text 10. Rimmer A, Phan H, Mathieson I, et al. : Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat Genet. 2014; 46 (8): 912–8. PubMed Abstract | Publisher Full Text | Free Full Text 11. Wang K, Li M, Hakonarson H: ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38 (16): e164. PubMed Abstract | Publisher Full Text | Free Full Text 12. Asai E, Wada T, Sakakibara Y, et al. : Analysis of mutations and recombination activity in RAG-deficient patients. Clin Immunol. 2011; 138 (2): 172–7. PubMed Abstract | Publisher Full Text 13. Buckley RH: Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004; 22 : 625–55. PubMed Abstract | Publisher Full Text 14. Shearer WT, Dunn E, Notarangelo LD, et al. : Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014; 133 (4): 1092–8. PubMed Abstract | Publisher Full Text | Free Full Text 15. Notarangelo LD, Kim MS, Walter JE, et al. : Human RAG mutations: biochemistry and clinical implications. Nat Rev Immunol. 2016; 16 (4): 234–246. PubMed Abstract | Publisher Full Text Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 18 Oct 2016 ADD YOUR COMMENT Comment Author details Author details 1 Department of Pediatrics, Institute of Maternal and Child Health, Government Medical College, Kozhikode, India 2 Academy of Scientific and Innovative Research (AcSIR), CSIR-IGIB, Delhi, India 3 Genomics and Molecular Medicine Unit, CSIR Institute of Genomics and Integrative Biology, Delhi, India 4 Apollo Speciality Hospital, Chennai, India 5 Department of Pathology, Government Medical College, Kozhikode, India 6 GN Ramachandran Knowledge Center for Genome Informatics, CSIR Institute of Genomics and Integrative Biology, Delhi, India Geeta Madathil Govindaraj Roles: Writing – Original Draft Preparation Shamsudheen Karuthedath Vellarikkal Roles: Data Curation, Methodology, Validation, Writing – Original Draft Preparation Rijith Jayarajan Roles: Data Curation, Methodology, Validation Rowmika Ravi Roles: Methodology, Validation, Writing – Original Draft Preparation Ankit Verma Roles: Data Curation, Methodology, Validation, Writing – Review & Editing Krishnan Chakkiyar Roles: Investigation Machinari Puthenpurayil Jayakrishnan Roles: Investigation Riyaz Arakkal Roles: Writing – Review & Editing Revathi Raj Roles: Investigation Rajeevan Kunnaruvath Roles: Investigation Sridhar Sivasubbu Roles: Conceptualization, Funding Acquisition, Resources, Writing – Original Draft Preparation, Writing – Review & Editing Vinod Scaria Roles: Conceptualization, Data Curation, Formal Analysis, Resources, Writing – Original Draft Preparation, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information SS and VS acknowledge funding from the Council of Scientific and Industrial Research (CSIR) India through Grant BSC0212. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Article Versions (2) version 2 Revised Published: 02 Oct 2017, 5:2532 https://doi.org/10.12688/f1000research.9473.2 version 1 Published: 18 Oct 2016, 5:2532 https://doi.org/10.12688/f1000research.9473.1 Copyright © 2017 Govindaraj GM et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Govindaraj GM, Karuthedath Vellarikkal S, Jayarajan R et al. Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.12688/f1000research.9473.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 2 VERSION 2 PUBLISHED 02 Oct 2017 Revised Views 0 Cite How to cite this report: Itliani P. Reviewer Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.13267.r26544 ) The direct URL for this report is: https://f1000research.com/articles/5-2532/v2#referee-response-26544 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 10 Oct 2017 Paola Itliani , Institute of Protein Biochemistry, National Research Council of Italy, Naples, Italy Approved VIEWS 0 https://doi.org/10.5256/f1000research.13267.r26544 No ... Continue reading READ ALL No further comments. Competing Interests: No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Itliani P. Reviewer Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.13267.r26544 ) The direct URL for this report is: https://f1000research.com/articles/5-2532/v2#referee-response-26544 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Buchbinder DK. Reviewer Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.13267.r26546 ) The direct URL for this report is: https://f1000research.com/articles/5-2532/v2#referee-response-26546 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 03 Oct 2017 David K. Buchbinder , Division of Hematology, Department of Pediatrics, Children's Hospital of Orange County, Orange, CA, USA Approved VIEWS 0 https://doi.org/10.5256/f1000research.13267.r26546 Thank you for the edits to the manuscript. I do think this is a very nice case description which highlights the value of next generation approaches in the diagnosis of primary immunodeficiency disorders. My only comments ... Continue reading READ ALL Thank you for the edits to the manuscript. I do think this is a very nice case description which highlights the value of next generation approaches in the diagnosis of primary immunodeficiency disorders. My only comments are very minor. Introduction: In the Introduction section I would be review the language and grammar. For example, in the first sentence - ".... of the humoral and/or cellular immune defense mechanism"... sounds awkward. The second sentence may also sound better if you get rid of "the" which starts the sentence. The third sentence where you talk about deficiency of RAG genes being associated with SCID seems awkward. The genes encode the proteins that are deficient. In this case RAG deficiency is associated with T-B-NK+ SCID. I know what you meant, but the sentence is confusing. The next sentence mentions that mutation in RAG1 is associated absence of VDJ recombination. That is not true for all RAG1 variants as you know. Please be careful in your choices of words. The sentence where you talk about an accurate molecular diagnosis being helpful for "genetic counseling for disease" is awkward. Disease what? The last word "gene" (before the sentence "The advent...." should be plural. Lastly, you only need to define the abbreviation RAG1 once. Case: You are missing a "he" in the sentence in which you give his birth weight. Define abbreviations like HIV ELISA, AFB, etc. Also, were you able to look at mitogens? That would be useful in defining SCID. What is leuconostoc? What were the doses and timing of the DLI? Any complications such as GVHD? What was the most recent chimerism assessment? Methods: Fine. Results: You already defined RAG1. Discussion: You already defned RAG1 and SCID. Please use the definition for SCID in the discussion. I would consider "suggested" instead of "was a pointer to". I would get rid of the words "are on the" in front of the word "wane". In the second paragraph you capitalized immunodeficiency. Why? You talk about other forms of SCID such as X-SCID, Jak3, etc. Did you consider other forms of T-B-NK+ SCID? I would consider added this into the discussion. Competing Interests: No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Buchbinder DK. Reviewer Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.13267.r26546 ) The direct URL for this report is: https://f1000research.com/articles/5-2532/v2#referee-response-26546 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Version 1 VERSION 1 PUBLISHED 18 Oct 2016 Views 0 Cite How to cite this report: Hammarström L. Reviewer Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.10202.r20355 ) The direct URL for this report is: https://f1000research.com/articles/5-2532/v1#referee-response-20355 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 20 Feb 2017 Lennart Hammarström , Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden Not Approved VIEWS 0 https://doi.org/10.5256/f1000research.10202.r20355 Govindaraj et al. report a typical SCID patient with a known mutation in Rag1 (p.E770K) with a previously known defective recombination activity and thus, there is very little novel information in this manuscript. In fact, the manuscript is already in ... Continue reading READ ALL Govindaraj et al. report a typical SCID patient with a known mutation in Rag1 (p.E770K) with a previously known defective recombination activity and thus, there is very little novel information in this manuscript. In fact, the manuscript is already in itself published in F1000 (October 18th, 2016) and available on the web. The mutation should simply be added to existing databases. Additional comments: The figure should be improved – providing the different domains. The pedigree (inheritance pattern is incomplete) - or simply state that the missing individuals were not sampled. Introduction should be more focussed on Rag 1. Immunization schedule (if any) for live vaccines could be of interest for the readers (but not necessary). In the methods section, uniformity should apply (cc, mm ul etc). The number of NK cells appear to be too high (higher than the total lymphocyte count). Gene names should be in italics and transcript IDs should be given. Abbreviations should be correctly used and introduced at the first time of presentation. Competing Interests: No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Hammarström L. Reviewer Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.10202.r20355 ) The direct URL for this report is: https://f1000research.com/articles/5-2532/v1#referee-response-20355 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Buchbinder DK. Reviewer Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.10202.r19588 ) The direct URL for this report is: https://f1000research.com/articles/5-2532/v1#referee-response-19588 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 31 Jan 2017 David K. Buchbinder , Division of Hematology, Department of Pediatrics, Children's Hospital of Orange County, Orange, CA, USA Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.10202.r19588 The authors provide a case report of a patient with severe combined immunodeficiency secondary to RAG deficiency. Whole exome sequencing was utilized to ensure a rapid and accurate diagnosis. Overall, the report is well written. Despite this there are some ... Continue reading READ ALL The authors provide a case report of a patient with severe combined immunodeficiency secondary to RAG deficiency. Whole exome sequencing was utilized to ensure a rapid and accurate diagnosis. Overall, the report is well written. Despite this there are some minor changes that should be considered. I also do not appreciate the novelty of this report and what it adds to the existing literature. The clinical diagnosis of severe combined immunodeficiency is clear. The routine use of next generation sequencing approaches are widely used to provide accurate and rapid diagnoses. Introduction Page 3: I would consider focusing the introduction on the topic of RAG deficiency. Page 3: I would also note that an accurate and timely diagnosis is vital to the provision of life-saving therapy. Page 3: At the end of the first paragraph the word “sometime” is missing an “s”. Page 3: In the last paragraph of the introduction you talk about a genetic variation E770K. A genetic variation in what gene? Please state RAG1 . Case Report Page 3: When talking about the patient weight, height, and head circumference I would add in percentiles. Page 3: Please define the abbreviation “PICU”. Page 3: I would review the units on measurements. I would consider using SI units. For example, please review the use of “mg%”. I would address this issue throughout the manuscript. Page 3: How was HIV and tuberculosis excluded? Page 3: Is chest X-Ray correct? Page 3: Was there any evidence of eosinophilia? Page 4: For the immunological evaluation - were antibody responses assessed? Were RA/RO populations assessed? Were T cell responses to mitogens assessed? Was TCR diversity assessed? Was maternal engraftment assessed? Page 4: Please define the abbreviation “IVIG”. Page 4: How was the CMV infection identified? Where was the “infection”? How was staph pneumonia identified? Page 4: I would consider adding a “Methods” section where you talk about the whole exome techniques used and confirmatory sequencing. I don’t really like how it is right in the middle of the case report. Page 4: In the 4 th paragraph I would italicize “RAG1”. This should be addressed throughout the manuscript. Page 4: You mention that the mutation was previously reported. This detracts a bit from the novelty. I would also consider noting the RAG activity that was assessed in-vitro from the citation. Discussion Page 4: You fail to use the abbreviation “SCID” in the first paragraph of the discussion which you defined earlier. Page 4: Please define the abbreviations “XR, Jak3, and ADA”. Page 4: I would include the portion about the transplant course in the case report section and not at the end of the discussion. I would add in additional details as well - what type of conditioning was used? Graft-versus-host-disease prophylaxis? What was the etiology of the hypertension? PRES? What was the organism isolated during sepsis? Any other post-transplant issues such as GVHD, VOD, etc.? Was engraftment assessed (i.e. lineage specific chimerism)? Competing Interests: No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Buchbinder DK. Reviewer Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.10202.r19588 ) The direct URL for this report is: https://f1000research.com/articles/5-2532/v1#referee-response-19588 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 02 Oct 2017 Vinod Scaria , GN Ramachandran Knowledge Center for Genome Informatics, CSIR Institute of Genomics and Integrative Biology, Delhi, India 02 Oct 2017 Author Response The authors provide a case report of a patient with severe combined immunodeficiency secondary to RAG deficiency. Whole exome sequencing was utilized to ensure a rapid and accurate diagnosis. Overall, ... Continue reading The authors provide a case report of a patient with severe combined immunodeficiency secondary to RAG deficiency. Whole exome sequencing was utilized to ensure a rapid and accurate diagnosis. Overall, the report is well written. Despite this there are some minor changes that should be considered. I also do not appreciate the novelty of this report and what it adds to the existing literature. The clinical diagnosis of severe combined immunodeficiency is clear. The routine use of next generation sequencing approaches are widely used to provide accurate and rapid diagnoses. Introduction Page 3: I would consider focusing the introduction on the topic of RAG deficiency. Clarification: Suggestions have been incorporated. Introduction is added with focus on RAG1 deficiency. Page 3: I would also note that an accurate and timely diagnosis is vital to the provision of life-saving therapy. Clarification: Suggestions have been incorporated. Page 3: At the end of the first paragraph the word “sometime” is missing an “s”. Clarification: Corrections has been incorporated. Page 3: In the last paragraph of the introduction you talk about a genetic variation E770K. A genetic variation in what gene? Please state RAG1 . Clarification: Suggestions have been incorporated. Case Report Page 3: When talking about the patient weight, height, and head circumference I would add in percentiles. Clarification: His weight, length and head circumference were below the 3 rd centile as per WHO Child Growth Standards. This is updated in the manuscript. Page 3: Please define the abbreviation “PICU”. Clarification: Suggestions have been incorporated. Page 3: I would review the units on measurements. I would consider using SI units. For example, please review the use of “mg%”. I would address this issue throughout the manuscript. Clarification: Ionized calcium was 0.28 mmol/L. Page 3: How was HIV and tuberculosis excluded? Clarification: The child’s mother was HIV ELISA negative and the child had a negative Mantoux test and negative gastric acid AFB stain. Page 3: Is chest X-Ray correct? Clarification: Lateral view of the Chest X Ray. Page 3: Was there any evidence of eosinophilia? Clarification: There was no evidence of eosinophilia Page 4: For the immunological evaluation - were antibody responses assessed? Were RA/RO populations assessed? Were T cell responses to mitogens assessed? Was TCR diversity assessed? Was maternal engraftment assessed? Clarification: Antibody responses, RA/RO populations, responses to mitogens, TCR diversity and maternal engraftment were not assessed. Page 4: Please define the abbreviation “IVIG”. Clarification: Suggestions have been incorporated. Page 4: How was the CMV infection identified? Where was the “infection”? How was staph pneumonia identified? Clarification: CMV infection was identified by DNA PCR. The child had disseminated CMV infection. Staph. pneumonia was identified by characteristic radiological findings and positive blood culture. Page 4: I would consider adding a “Methods” section where you talk about the whole exome techniques used and confirmatory sequencing. I don’t really like how it is right in the middle of the case report. Clarification: Suggestions have been incorporated. Page 4: In the 4 th paragraph I would italicize “RAG1”. This should be addressed throughout the manuscript. Clarification: Suggestions have been incorporated. Page 4: You mention that the mutation was previously reported. This detracts a bit from the novelty. I would also consider noting the RAG activity that was assessed in-vitro from the citation. Clarification: We are not claiming that the mutation is novel. We are pointing that the variation is so rare that it is reported only once. In-vitro assay for RAG activity from citation is noted down in manuscript. Discussion Page 4: You fail to use the abbreviation “SCID” in the first paragraph of the discussion which you defined earlier. Clarification: Suggestions have been incorporated. Page 4: Please define the abbreviations “XR, Jak3, and ADA”. Clarification: Suggestions have been incorporated. Page 4: I would include the portion about the transplant course in the case report section and not at the end of the discussion. I would add in additional details as well - what type of conditioning was used? Graft-versus-host-disease prophylaxis? What was the etiology of the hypertension? PRES? What was the organism isolated during sepsis? Any other post-transplant issues such as GVHD, VOD, etc.? Was engraftment assessed (i.e. lineage specific chimerism). Clarification: Suggestion have been incorporated. The hypertension is an inadvertent typographical error. It should read ‘hypotension’. There was no issue of GVHD or VOD. The authors provide a case report of a patient with severe combined immunodeficiency secondary to RAG deficiency. Whole exome sequencing was utilized to ensure a rapid and accurate diagnosis. Overall, the report is well written. Despite this there are some minor changes that should be considered. I also do not appreciate the novelty of this report and what it adds to the existing literature. The clinical diagnosis of severe combined immunodeficiency is clear. The routine use of next generation sequencing approaches are widely used to provide accurate and rapid diagnoses. Introduction Page 3: I would consider focusing the introduction on the topic of RAG deficiency. Clarification: Suggestions have been incorporated. Introduction is added with focus on RAG1 deficiency. Page 3: I would also note that an accurate and timely diagnosis is vital to the provision of life-saving therapy. Clarification: Suggestions have been incorporated. Page 3: At the end of the first paragraph the word “sometime” is missing an “s”. Clarification: Corrections has been incorporated. Page 3: In the last paragraph of the introduction you talk about a genetic variation E770K. A genetic variation in what gene? Please state RAG1 . Clarification: Suggestions have been incorporated. Case Report Page 3: When talking about the patient weight, height, and head circumference I would add in percentiles. Clarification: His weight, length and head circumference were below the 3 rd centile as per WHO Child Growth Standards. This is updated in the manuscript. Page 3: Please define the abbreviation “PICU”. Clarification: Suggestions have been incorporated. Page 3: I would review the units on measurements. I would consider using SI units. For example, please review the use of “mg%”. I would address this issue throughout the manuscript. Clarification: Ionized calcium was 0.28 mmol/L. Page 3: How was HIV and tuberculosis excluded? Clarification: The child’s mother was HIV ELISA negative and the child had a negative Mantoux test and negative gastric acid AFB stain. Page 3: Is chest X-Ray correct? Clarification: Lateral view of the Chest X Ray. Page 3: Was there any evidence of eosinophilia? Clarification: There was no evidence of eosinophilia Page 4: For the immunological evaluation - were antibody responses assessed? Were RA/RO populations assessed? Were T cell responses to mitogens assessed? Was TCR diversity assessed? Was maternal engraftment assessed? Clarification: Antibody responses, RA/RO populations, responses to mitogens, TCR diversity and maternal engraftment were not assessed. Page 4: Please define the abbreviation “IVIG”. Clarification: Suggestions have been incorporated. Page 4: How was the CMV infection identified? Where was the “infection”? How was staph pneumonia identified? Clarification: CMV infection was identified by DNA PCR. The child had disseminated CMV infection. Staph. pneumonia was identified by characteristic radiological findings and positive blood culture. Page 4: I would consider adding a “Methods” section where you talk about the whole exome techniques used and confirmatory sequencing. I don’t really like how it is right in the middle of the case report. Clarification: Suggestions have been incorporated. Page 4: In the 4 th paragraph I would italicize “RAG1”. This should be addressed throughout the manuscript. Clarification: Suggestions have been incorporated. Page 4: You mention that the mutation was previously reported. This detracts a bit from the novelty. I would also consider noting the RAG activity that was assessed in-vitro from the citation. Clarification: We are not claiming that the mutation is novel. We are pointing that the variation is so rare that it is reported only once. In-vitro assay for RAG activity from citation is noted down in manuscript. Discussion Page 4: You fail to use the abbreviation “SCID” in the first paragraph of the discussion which you defined earlier. Clarification: Suggestions have been incorporated. Page 4: Please define the abbreviations “XR, Jak3, and ADA”. Clarification: Suggestions have been incorporated. Page 4: I would include the portion about the transplant course in the case report section and not at the end of the discussion. I would add in additional details as well - what type of conditioning was used? Graft-versus-host-disease prophylaxis? What was the etiology of the hypertension? PRES? What was the organism isolated during sepsis? Any other post-transplant issues such as GVHD, VOD, etc.? Was engraftment assessed (i.e. lineage specific chimerism). Clarification: Suggestion have been incorporated. The hypertension is an inadvertent typographical error. It should read ‘hypotension’. There was no issue of GVHD or VOD. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 02 Oct 2017 Vinod Scaria , GN Ramachandran Knowledge Center for Genome Informatics, CSIR Institute of Genomics and Integrative Biology, Delhi, India 02 Oct 2017 Author Response The authors provide a case report of a patient with severe combined immunodeficiency secondary to RAG deficiency. Whole exome sequencing was utilized to ensure a rapid and accurate diagnosis. Overall, ... Continue reading The authors provide a case report of a patient with severe combined immunodeficiency secondary to RAG deficiency. Whole exome sequencing was utilized to ensure a rapid and accurate diagnosis. Overall, the report is well written. Despite this there are some minor changes that should be considered. I also do not appreciate the novelty of this report and what it adds to the existing literature. The clinical diagnosis of severe combined immunodeficiency is clear. The routine use of next generation sequencing approaches are widely used to provide accurate and rapid diagnoses. Introduction Page 3: I would consider focusing the introduction on the topic of RAG deficiency. Clarification: Suggestions have been incorporated. Introduction is added with focus on RAG1 deficiency. Page 3: I would also note that an accurate and timely diagnosis is vital to the provision of life-saving therapy. Clarification: Suggestions have been incorporated. Page 3: At the end of the first paragraph the word “sometime” is missing an “s”. Clarification: Corrections has been incorporated. Page 3: In the last paragraph of the introduction you talk about a genetic variation E770K. A genetic variation in what gene? Please state RAG1 . Clarification: Suggestions have been incorporated. Case Report Page 3: When talking about the patient weight, height, and head circumference I would add in percentiles. Clarification: His weight, length and head circumference were below the 3 rd centile as per WHO Child Growth Standards. This is updated in the manuscript. Page 3: Please define the abbreviation “PICU”. Clarification: Suggestions have been incorporated. Page 3: I would review the units on measurements. I would consider using SI units. For example, please review the use of “mg%”. I would address this issue throughout the manuscript. Clarification: Ionized calcium was 0.28 mmol/L. Page 3: How was HIV and tuberculosis excluded? Clarification: The child’s mother was HIV ELISA negative and the child had a negative Mantoux test and negative gastric acid AFB stain. Page 3: Is chest X-Ray correct? Clarification: Lateral view of the Chest X Ray. Page 3: Was there any evidence of eosinophilia? Clarification: There was no evidence of eosinophilia Page 4: For the immunological evaluation - were antibody responses assessed? Were RA/RO populations assessed? Were T cell responses to mitogens assessed? Was TCR diversity assessed? Was maternal engraftment assessed? Clarification: Antibody responses, RA/RO populations, responses to mitogens, TCR diversity and maternal engraftment were not assessed. Page 4: Please define the abbreviation “IVIG”. Clarification: Suggestions have been incorporated. Page 4: How was the CMV infection identified? Where was the “infection”? How was staph pneumonia identified? Clarification: CMV infection was identified by DNA PCR. The child had disseminated CMV infection. Staph. pneumonia was identified by characteristic radiological findings and positive blood culture. Page 4: I would consider adding a “Methods” section where you talk about the whole exome techniques used and confirmatory sequencing. I don’t really like how it is right in the middle of the case report. Clarification: Suggestions have been incorporated. Page 4: In the 4 th paragraph I would italicize “RAG1”. This should be addressed throughout the manuscript. Clarification: Suggestions have been incorporated. Page 4: You mention that the mutation was previously reported. This detracts a bit from the novelty. I would also consider noting the RAG activity that was assessed in-vitro from the citation. Clarification: We are not claiming that the mutation is novel. We are pointing that the variation is so rare that it is reported only once. In-vitro assay for RAG activity from citation is noted down in manuscript. Discussion Page 4: You fail to use the abbreviation “SCID” in the first paragraph of the discussion which you defined earlier. Clarification: Suggestions have been incorporated. Page 4: Please define the abbreviations “XR, Jak3, and ADA”. Clarification: Suggestions have been incorporated. Page 4: I would include the portion about the transplant course in the case report section and not at the end of the discussion. I would add in additional details as well - what type of conditioning was used? Graft-versus-host-disease prophylaxis? What was the etiology of the hypertension? PRES? What was the organism isolated during sepsis? Any other post-transplant issues such as GVHD, VOD, etc.? Was engraftment assessed (i.e. lineage specific chimerism). Clarification: Suggestion have been incorporated. The hypertension is an inadvertent typographical error. It should read ‘hypotension’. There was no issue of GVHD or VOD. The authors provide a case report of a patient with severe combined immunodeficiency secondary to RAG deficiency. Whole exome sequencing was utilized to ensure a rapid and accurate diagnosis. Overall, the report is well written. Despite this there are some minor changes that should be considered. I also do not appreciate the novelty of this report and what it adds to the existing literature. The clinical diagnosis of severe combined immunodeficiency is clear. The routine use of next generation sequencing approaches are widely used to provide accurate and rapid diagnoses. Introduction Page 3: I would consider focusing the introduction on the topic of RAG deficiency. Clarification: Suggestions have been incorporated. Introduction is added with focus on RAG1 deficiency. Page 3: I would also note that an accurate and timely diagnosis is vital to the provision of life-saving therapy. Clarification: Suggestions have been incorporated. Page 3: At the end of the first paragraph the word “sometime” is missing an “s”. Clarification: Corrections has been incorporated. Page 3: In the last paragraph of the introduction you talk about a genetic variation E770K. A genetic variation in what gene? Please state RAG1 . Clarification: Suggestions have been incorporated. Case Report Page 3: When talking about the patient weight, height, and head circumference I would add in percentiles. Clarification: His weight, length and head circumference were below the 3 rd centile as per WHO Child Growth Standards. This is updated in the manuscript. Page 3: Please define the abbreviation “PICU”. Clarification: Suggestions have been incorporated. Page 3: I would review the units on measurements. I would consider using SI units. For example, please review the use of “mg%”. I would address this issue throughout the manuscript. Clarification: Ionized calcium was 0.28 mmol/L. Page 3: How was HIV and tuberculosis excluded? Clarification: The child’s mother was HIV ELISA negative and the child had a negative Mantoux test and negative gastric acid AFB stain. Page 3: Is chest X-Ray correct? Clarification: Lateral view of the Chest X Ray. Page 3: Was there any evidence of eosinophilia? Clarification: There was no evidence of eosinophilia Page 4: For the immunological evaluation - were antibody responses assessed? Were RA/RO populations assessed? Were T cell responses to mitogens assessed? Was TCR diversity assessed? Was maternal engraftment assessed? Clarification: Antibody responses, RA/RO populations, responses to mitogens, TCR diversity and maternal engraftment were not assessed. Page 4: Please define the abbreviation “IVIG”. Clarification: Suggestions have been incorporated. Page 4: How was the CMV infection identified? Where was the “infection”? How was staph pneumonia identified? Clarification: CMV infection was identified by DNA PCR. The child had disseminated CMV infection. Staph. pneumonia was identified by characteristic radiological findings and positive blood culture. Page 4: I would consider adding a “Methods” section where you talk about the whole exome techniques used and confirmatory sequencing. I don’t really like how it is right in the middle of the case report. Clarification: Suggestions have been incorporated. Page 4: In the 4 th paragraph I would italicize “RAG1”. This should be addressed throughout the manuscript. Clarification: Suggestions have been incorporated. Page 4: You mention that the mutation was previously reported. This detracts a bit from the novelty. I would also consider noting the RAG activity that was assessed in-vitro from the citation. Clarification: We are not claiming that the mutation is novel. We are pointing that the variation is so rare that it is reported only once. In-vitro assay for RAG activity from citation is noted down in manuscript. Discussion Page 4: You fail to use the abbreviation “SCID” in the first paragraph of the discussion which you defined earlier. Clarification: Suggestions have been incorporated. Page 4: Please define the abbreviations “XR, Jak3, and ADA”. Clarification: Suggestions have been incorporated. Page 4: I would include the portion about the transplant course in the case report section and not at the end of the discussion. I would add in additional details as well - what type of conditioning was used? Graft-versus-host-disease prophylaxis? What was the etiology of the hypertension? PRES? What was the organism isolated during sepsis? Any other post-transplant issues such as GVHD, VOD, etc.? Was engraftment assessed (i.e. lineage specific chimerism). Clarification: Suggestion have been incorporated. The hypertension is an inadvertent typographical error. It should read ‘hypotension’. There was no issue of GVHD or VOD. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Itliani P. Reviewer Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.10202.r17720 ) The direct URL for this report is: https://f1000research.com/articles/5-2532/v1#referee-response-17720 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 16 Nov 2016 Paola Itliani , Institute of Protein Biochemistry, National Research Council of Italy, Naples, Italy Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.10202.r17720 The manuscript “Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency” is the description of a case report, that is a child as a supposed case of SCID. Exactly, the authors found ... Continue reading READ ALL The manuscript “Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency” is the description of a case report, that is a child as a supposed case of SCID. Exactly, the authors found a homozygous variation c.2308G>A by whole exome sequencing and they hypothesized that this variant is associated with the disease. All the sections of the manuscript are well presented and written (title, abstract, content and discussion). However, there are two points that I would like to comment: In the introduction the authors wrote that there are over a dozen genes known to be implicated in the disease. So, what about these genes in this case report? By performing a whole exome sequencing, did they also observed the variants of these genes? if yes or not, please comment! In order to explain the functional consequences of the mutated protein, the authors write “The variation causes an amino acid change p.E770K, which lies on RAG1 domain of the protein……Incidentally the mutation was previously reported and analysis suggested a significantly reduced recombination activity” referring to work of Asai E et al . Clin Immunol. 2011. In Asai’s work the nucleotide mutation is referred as 2420 G>A with a E770K effect. The position of nucleotide between the two works is different, but the authors of the manuscript declare the same position for amino acid change and the same reduced recombination activity. Please, specify/insert the RS ID number of the homozygous variation. Competing Interests: No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Itliani P. Reviewer Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.10202.r17720 ) The direct URL for this report is: https://f1000research.com/articles/5-2532/v1#referee-response-17720 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 02 Oct 2017 Vinod Scaria , GN Ramachandran Knowledge Center for Genome Informatics, CSIR Institute of Genomics and Integrative Biology, Delhi, India 02 Oct 2017 Author Response The manuscript “Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency” is the description of a case report, that is a child ... Continue reading The manuscript “Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency” is the description of a case report, that is a child as a supposed case of SCID. Exactly, the authors found a homozygous variation c.2308G>A by whole exome sequencing and they hypothesized that this variant is associated with the disease. All the sections of the manuscript are well presented and written (title, abstract, content and discussion). However, there are two points that I would like to comment: 1. In the introduction the authors wrote that there are over a dozen genes known to be implicated in the disease. So, what about these genes in this case report? By performing a whole exome sequencing, did they also observed the variants of these genes? if yes or not, please comment Clarification 1: We have observed the variations in the genes, which are previously reported with primary immunodeficiency. The prioritized variations are shown in table uploaded in answer to reviewer’s comments. (Sent to editor while uploading revised version). Among the variations, the RAG1:c.2308G>A:p.E770K variation was prioritised due to pathogenic and rarity of variation. 2. In order to explain the functional consequences of the mutated protein, the authors write “The variation causes an amino acid change p.E770K, which lies on RAG1 domain of the protein……Incidentally the mutation was previously reported and analysis suggested a significantly reduced recombination activity” referring to work of Asai E et al . Clin Immunol. 2011. In Asai’s work the nucleotide mutation is referred as 2420 G>A with a E770K effect. The position of nucleotide between the two works is different, but the authors of the manuscript declare the same position for amino acid change and the same reduced recombination activity. Please, specify/insert the RS ID number of the homozygous variation. Clarification 2: In the original publication by Asai et al. 2011, the nucleotide position is mentioned as c.2420G>A. While the position of amino acid is clear from the publication, we are not sure if nucleotide position denotes the position in cDNA or other. In our case, we mentioned the cDNA change as c.2308G>A and amino acid change as p.E770K. We clearly indicated the change in cDNA and it is also the reported nomenclature from database. For reference, Cosmic mutation ID: COSM3447065. The rsID for mutation is rs768260595. The manuscript “Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency” is the description of a case report, that is a child as a supposed case of SCID. Exactly, the authors found a homozygous variation c.2308G>A by whole exome sequencing and they hypothesized that this variant is associated with the disease. All the sections of the manuscript are well presented and written (title, abstract, content and discussion). However, there are two points that I would like to comment: 1. In the introduction the authors wrote that there are over a dozen genes known to be implicated in the disease. So, what about these genes in this case report? By performing a whole exome sequencing, did they also observed the variants of these genes? if yes or not, please comment Clarification 1: We have observed the variations in the genes, which are previously reported with primary immunodeficiency. The prioritized variations are shown in table uploaded in answer to reviewer’s comments. (Sent to editor while uploading revised version). Among the variations, the RAG1:c.2308G>A:p.E770K variation was prioritised due to pathogenic and rarity of variation. 2. In order to explain the functional consequences of the mutated protein, the authors write “The variation causes an amino acid change p.E770K, which lies on RAG1 domain of the protein……Incidentally the mutation was previously reported and analysis suggested a significantly reduced recombination activity” referring to work of Asai E et al . Clin Immunol. 2011. In Asai’s work the nucleotide mutation is referred as 2420 G>A with a E770K effect. The position of nucleotide between the two works is different, but the authors of the manuscript declare the same position for amino acid change and the same reduced recombination activity. Please, specify/insert the RS ID number of the homozygous variation. Clarification 2: In the original publication by Asai et al. 2011, the nucleotide position is mentioned as c.2420G>A. While the position of amino acid is clear from the publication, we are not sure if nucleotide position denotes the position in cDNA or other. In our case, we mentioned the cDNA change as c.2308G>A and amino acid change as p.E770K. We clearly indicated the change in cDNA and it is also the reported nomenclature from database. For reference, Cosmic mutation ID: COSM3447065. The rsID for mutation is rs768260595. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 02 Oct 2017 Vinod Scaria , GN Ramachandran Knowledge Center for Genome Informatics, CSIR Institute of Genomics and Integrative Biology, Delhi, India 02 Oct 2017 Author Response The manuscript “Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency” is the description of a case report, that is a child ... Continue reading The manuscript “Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency” is the description of a case report, that is a child as a supposed case of SCID. Exactly, the authors found a homozygous variation c.2308G>A by whole exome sequencing and they hypothesized that this variant is associated with the disease. All the sections of the manuscript are well presented and written (title, abstract, content and discussion). However, there are two points that I would like to comment: 1. In the introduction the authors wrote that there are over a dozen genes known to be implicated in the disease. So, what about these genes in this case report? By performing a whole exome sequencing, did they also observed the variants of these genes? if yes or not, please comment Clarification 1: We have observed the variations in the genes, which are previously reported with primary immunodeficiency. The prioritized variations are shown in table uploaded in answer to reviewer’s comments. (Sent to editor while uploading revised version). Among the variations, the RAG1:c.2308G>A:p.E770K variation was prioritised due to pathogenic and rarity of variation. 2. In order to explain the functional consequences of the mutated protein, the authors write “The variation causes an amino acid change p.E770K, which lies on RAG1 domain of the protein……Incidentally the mutation was previously reported and analysis suggested a significantly reduced recombination activity” referring to work of Asai E et al . Clin Immunol. 2011. In Asai’s work the nucleotide mutation is referred as 2420 G>A with a E770K effect. The position of nucleotide between the two works is different, but the authors of the manuscript declare the same position for amino acid change and the same reduced recombination activity. Please, specify/insert the RS ID number of the homozygous variation. Clarification 2: In the original publication by Asai et al. 2011, the nucleotide position is mentioned as c.2420G>A. While the position of amino acid is clear from the publication, we are not sure if nucleotide position denotes the position in cDNA or other. In our case, we mentioned the cDNA change as c.2308G>A and amino acid change as p.E770K. We clearly indicated the change in cDNA and it is also the reported nomenclature from database. For reference, Cosmic mutation ID: COSM3447065. The rsID for mutation is rs768260595. The manuscript “Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency” is the description of a case report, that is a child as a supposed case of SCID. Exactly, the authors found a homozygous variation c.2308G>A by whole exome sequencing and they hypothesized that this variant is associated with the disease. All the sections of the manuscript are well presented and written (title, abstract, content and discussion). However, there are two points that I would like to comment: 1. In the introduction the authors wrote that there are over a dozen genes known to be implicated in the disease. So, what about these genes in this case report? By performing a whole exome sequencing, did they also observed the variants of these genes? if yes or not, please comment Clarification 1: We have observed the variations in the genes, which are previously reported with primary immunodeficiency. The prioritized variations are shown in table uploaded in answer to reviewer’s comments. (Sent to editor while uploading revised version). Among the variations, the RAG1:c.2308G>A:p.E770K variation was prioritised due to pathogenic and rarity of variation. 2. In order to explain the functional consequences of the mutated protein, the authors write “The variation causes an amino acid change p.E770K, which lies on RAG1 domain of the protein……Incidentally the mutation was previously reported and analysis suggested a significantly reduced recombination activity” referring to work of Asai E et al . Clin Immunol. 2011. In Asai’s work the nucleotide mutation is referred as 2420 G>A with a E770K effect. The position of nucleotide between the two works is different, but the authors of the manuscript declare the same position for amino acid change and the same reduced recombination activity. Please, specify/insert the RS ID number of the homozygous variation. Clarification 2: In the original publication by Asai et al. 2011, the nucleotide position is mentioned as c.2420G>A. While the position of amino acid is clear from the publication, we are not sure if nucleotide position denotes the position in cDNA or other. In our case, we mentioned the cDNA change as c.2308G>A and amino acid change as p.E770K. We clearly indicated the change in cDNA and it is also the reported nomenclature from database. For reference, Cosmic mutation ID: COSM3447065. The rsID for mutation is rs768260595. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 18 Oct 2016 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 3 Version 2 (revision) 02 Oct 17 read read Version 1 18 Oct 16 read read read Paola Itliani , National Research Council of Italy, Naples, Italy David K. Buchbinder , Children's Hospital of Orange County, Orange, USA Lennart Hammarström , Karolinska Institutet, Stockholm, Sweden Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2017 Itliani P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 10 Oct 2017 | for Version 2 Paola Itliani , Institute of Protein Biochemistry, National Research Council of Italy, Naples, Italy 0 Views copyright © 2017 Itliani P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions No further comments. Competing Interests No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Itliani P. Peer Review Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.13267.r26544) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/5-2532/v2#referee-response-26544 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2017 Buchbinder D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 03 Oct 2017 | for Version 2 David K. Buchbinder , Division of Hematology, Department of Pediatrics, Children's Hospital of Orange County, Orange, CA, USA 0 Views copyright © 2017 Buchbinder D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Thank you for the edits to the manuscript. I do think this is a very nice case description which highlights the value of next generation approaches in the diagnosis of primary immunodeficiency disorders. My only comments are very minor. Introduction: In the Introduction section I would be review the language and grammar. For example, in the first sentence - ".... of the humoral and/or cellular immune defense mechanism"... sounds awkward. The second sentence may also sound better if you get rid of "the" which starts the sentence. The third sentence where you talk about deficiency of RAG genes being associated with SCID seems awkward. The genes encode the proteins that are deficient. In this case RAG deficiency is associated with T-B-NK+ SCID. I know what you meant, but the sentence is confusing. The next sentence mentions that mutation in RAG1 is associated absence of VDJ recombination. That is not true for all RAG1 variants as you know. Please be careful in your choices of words. The sentence where you talk about an accurate molecular diagnosis being helpful for "genetic counseling for disease" is awkward. Disease what? The last word "gene" (before the sentence "The advent...." should be plural. Lastly, you only need to define the abbreviation RAG1 once. Case: You are missing a "he" in the sentence in which you give his birth weight. Define abbreviations like HIV ELISA, AFB, etc. Also, were you able to look at mitogens? That would be useful in defining SCID. What is leuconostoc? What were the doses and timing of the DLI? Any complications such as GVHD? What was the most recent chimerism assessment? Methods: Fine. Results: You already defined RAG1. Discussion: You already defned RAG1 and SCID. Please use the definition for SCID in the discussion. I would consider "suggested" instead of "was a pointer to". I would get rid of the words "are on the" in front of the word "wane". In the second paragraph you capitalized immunodeficiency. Why? You talk about other forms of SCID such as X-SCID, Jak3, etc. Did you consider other forms of T-B-NK+ SCID? I would consider added this into the discussion. Competing Interests No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Buchbinder DK. Peer Review Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.13267.r26546) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/5-2532/v2#referee-response-26546 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2017 Hammarström L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 20 Feb 2017 | for Version 1 Lennart Hammarström , Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden 0 Views copyright © 2017 Hammarström L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Not Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Govindaraj et al. report a typical SCID patient with a known mutation in Rag1 (p.E770K) with a previously known defective recombination activity and thus, there is very little novel information in this manuscript. In fact, the manuscript is already in itself published in F1000 (October 18th, 2016) and available on the web. The mutation should simply be added to existing databases. Additional comments: The figure should be improved – providing the different domains. The pedigree (inheritance pattern is incomplete) - or simply state that the missing individuals were not sampled. Introduction should be more focussed on Rag 1. Immunization schedule (if any) for live vaccines could be of interest for the readers (but not necessary). In the methods section, uniformity should apply (cc, mm ul etc). The number of NK cells appear to be too high (higher than the total lymphocyte count). Gene names should be in italics and transcript IDs should be given. Abbreviations should be correctly used and introduced at the first time of presentation. Competing Interests No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. reply Respond to this report Responses (0) Hammarström L. Peer Review Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.10202.r20355) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/5-2532/v1#referee-response-20355 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2017 Buchbinder D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 31 Jan 2017 | for Version 1 David K. Buchbinder , Division of Hematology, Department of Pediatrics, Children's Hospital of Orange County, Orange, CA, USA 0 Views copyright © 2017 Buchbinder D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The authors provide a case report of a patient with severe combined immunodeficiency secondary to RAG deficiency. Whole exome sequencing was utilized to ensure a rapid and accurate diagnosis. Overall, the report is well written. Despite this there are some minor changes that should be considered. I also do not appreciate the novelty of this report and what it adds to the existing literature. The clinical diagnosis of severe combined immunodeficiency is clear. The routine use of next generation sequencing approaches are widely used to provide accurate and rapid diagnoses. Introduction Page 3: I would consider focusing the introduction on the topic of RAG deficiency. Page 3: I would also note that an accurate and timely diagnosis is vital to the provision of life-saving therapy. Page 3: At the end of the first paragraph the word “sometime” is missing an “s”. Page 3: In the last paragraph of the introduction you talk about a genetic variation E770K. A genetic variation in what gene? Please state RAG1 . Case Report Page 3: When talking about the patient weight, height, and head circumference I would add in percentiles. Page 3: Please define the abbreviation “PICU”. Page 3: I would review the units on measurements. I would consider using SI units. For example, please review the use of “mg%”. I would address this issue throughout the manuscript. Page 3: How was HIV and tuberculosis excluded? Page 3: Is chest X-Ray correct? Page 3: Was there any evidence of eosinophilia? Page 4: For the immunological evaluation - were antibody responses assessed? Were RA/RO populations assessed? Were T cell responses to mitogens assessed? Was TCR diversity assessed? Was maternal engraftment assessed? Page 4: Please define the abbreviation “IVIG”. Page 4: How was the CMV infection identified? Where was the “infection”? How was staph pneumonia identified? Page 4: I would consider adding a “Methods” section where you talk about the whole exome techniques used and confirmatory sequencing. I don’t really like how it is right in the middle of the case report. Page 4: In the 4 th paragraph I would italicize “RAG1”. This should be addressed throughout the manuscript. Page 4: You mention that the mutation was previously reported. This detracts a bit from the novelty. I would also consider noting the RAG activity that was assessed in-vitro from the citation. Discussion Page 4: You fail to use the abbreviation “SCID” in the first paragraph of the discussion which you defined earlier. Page 4: Please define the abbreviations “XR, Jak3, and ADA”. Page 4: I would include the portion about the transplant course in the case report section and not at the end of the discussion. I would add in additional details as well - what type of conditioning was used? Graft-versus-host-disease prophylaxis? What was the etiology of the hypertension? PRES? What was the organism isolated during sepsis? Any other post-transplant issues such as GVHD, VOD, etc.? Was engraftment assessed (i.e. lineage specific chimerism)? Competing Interests No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 02 Oct 2017 Vinod Scaria, GN Ramachandran Knowledge Center for Genome Informatics, CSIR Institute of Genomics and Integrative Biology, Delhi, India The authors provide a case report of a patient with severe combined immunodeficiency secondary to RAG deficiency. Whole exome sequencing was utilized to ensure a rapid and accurate diagnosis. Overall, the report is well written. Despite this there are some minor changes that should be considered. I also do not appreciate the novelty of this report and what it adds to the existing literature. The clinical diagnosis of severe combined immunodeficiency is clear. The routine use of next generation sequencing approaches are widely used to provide accurate and rapid diagnoses. Introduction Page 3: I would consider focusing the introduction on the topic of RAG deficiency. Clarification: Suggestions have been incorporated. Introduction is added with focus on RAG1 deficiency. Page 3: I would also note that an accurate and timely diagnosis is vital to the provision of life-saving therapy. Clarification: Suggestions have been incorporated. Page 3: At the end of the first paragraph the word “sometime” is missing an “s”. Clarification: Corrections has been incorporated. Page 3: In the last paragraph of the introduction you talk about a genetic variation E770K. A genetic variation in what gene? Please state RAG1 . Clarification: Suggestions have been incorporated. Case Report Page 3: When talking about the patient weight, height, and head circumference I would add in percentiles. Clarification: His weight, length and head circumference were below the 3 rd centile as per WHO Child Growth Standards. This is updated in the manuscript. Page 3: Please define the abbreviation “PICU”. Clarification: Suggestions have been incorporated. Page 3: I would review the units on measurements. I would consider using SI units. For example, please review the use of “mg%”. I would address this issue throughout the manuscript. Clarification: Ionized calcium was 0.28 mmol/L. Page 3: How was HIV and tuberculosis excluded? Clarification: The child’s mother was HIV ELISA negative and the child had a negative Mantoux test and negative gastric acid AFB stain. Page 3: Is chest X-Ray correct? Clarification: Lateral view of the Chest X Ray. Page 3: Was there any evidence of eosinophilia? Clarification: There was no evidence of eosinophilia Page 4: For the immunological evaluation - were antibody responses assessed? Were RA/RO populations assessed? Were T cell responses to mitogens assessed? Was TCR diversity assessed? Was maternal engraftment assessed? Clarification: Antibody responses, RA/RO populations, responses to mitogens, TCR diversity and maternal engraftment were not assessed. Page 4: Please define the abbreviation “IVIG”. Clarification: Suggestions have been incorporated. Page 4: How was the CMV infection identified? Where was the “infection”? How was staph pneumonia identified? Clarification: CMV infection was identified by DNA PCR. The child had disseminated CMV infection. Staph. pneumonia was identified by characteristic radiological findings and positive blood culture. Page 4: I would consider adding a “Methods” section where you talk about the whole exome techniques used and confirmatory sequencing. I don’t really like how it is right in the middle of the case report. Clarification: Suggestions have been incorporated. Page 4: In the 4 th paragraph I would italicize “RAG1”. This should be addressed throughout the manuscript. Clarification: Suggestions have been incorporated. Page 4: You mention that the mutation was previously reported. This detracts a bit from the novelty. I would also consider noting the RAG activity that was assessed in-vitro from the citation. Clarification: We are not claiming that the mutation is novel. We are pointing that the variation is so rare that it is reported only once. In-vitro assay for RAG activity from citation is noted down in manuscript. Discussion Page 4: You fail to use the abbreviation “SCID” in the first paragraph of the discussion which you defined earlier. Clarification: Suggestions have been incorporated. Page 4: Please define the abbreviations “XR, Jak3, and ADA”. Clarification: Suggestions have been incorporated. Page 4: I would include the portion about the transplant course in the case report section and not at the end of the discussion. I would add in additional details as well - what type of conditioning was used? Graft-versus-host-disease prophylaxis? What was the etiology of the hypertension? PRES? What was the organism isolated during sepsis? Any other post-transplant issues such as GVHD, VOD, etc.? Was engraftment assessed (i.e. lineage specific chimerism). Clarification: Suggestion have been incorporated. The hypertension is an inadvertent typographical error. It should read ‘hypotension’. There was no issue of GVHD or VOD. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Buchbinder DK. Peer Review Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.10202.r19588) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/5-2532/v1#referee-response-19588 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2016 Itliani P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 16 Nov 2016 | for Version 1 Paola Itliani , Institute of Protein Biochemistry, National Research Council of Italy, Naples, Italy 0 Views copyright © 2016 Itliani P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The manuscript “Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency” is the description of a case report, that is a child as a supposed case of SCID. Exactly, the authors found a homozygous variation c.2308G>A by whole exome sequencing and they hypothesized that this variant is associated with the disease. All the sections of the manuscript are well presented and written (title, abstract, content and discussion). However, there are two points that I would like to comment: In the introduction the authors wrote that there are over a dozen genes known to be implicated in the disease. So, what about these genes in this case report? By performing a whole exome sequencing, did they also observed the variants of these genes? if yes or not, please comment! In order to explain the functional consequences of the mutated protein, the authors write “The variation causes an amino acid change p.E770K, which lies on RAG1 domain of the protein……Incidentally the mutation was previously reported and analysis suggested a significantly reduced recombination activity” referring to work of Asai E et al . Clin Immunol. 2011. In Asai’s work the nucleotide mutation is referred as 2420 G>A with a E770K effect. The position of nucleotide between the two works is different, but the authors of the manuscript declare the same position for amino acid change and the same reduced recombination activity. Please, specify/insert the RS ID number of the homozygous variation. Competing Interests No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 02 Oct 2017 Vinod Scaria, GN Ramachandran Knowledge Center for Genome Informatics, CSIR Institute of Genomics and Integrative Biology, Delhi, India The manuscript “Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency” is the description of a case report, that is a child as a supposed case of SCID. Exactly, the authors found a homozygous variation c.2308G>A by whole exome sequencing and they hypothesized that this variant is associated with the disease. All the sections of the manuscript are well presented and written (title, abstract, content and discussion). However, there are two points that I would like to comment: 1. In the introduction the authors wrote that there are over a dozen genes known to be implicated in the disease. So, what about these genes in this case report? By performing a whole exome sequencing, did they also observed the variants of these genes? if yes or not, please comment Clarification 1: We have observed the variations in the genes, which are previously reported with primary immunodeficiency. The prioritized variations are shown in table uploaded in answer to reviewer’s comments. (Sent to editor while uploading revised version). Among the variations, the RAG1:c.2308G>A:p.E770K variation was prioritised due to pathogenic and rarity of variation. 2. In order to explain the functional consequences of the mutated protein, the authors write “The variation causes an amino acid change p.E770K, which lies on RAG1 domain of the protein……Incidentally the mutation was previously reported and analysis suggested a significantly reduced recombination activity” referring to work of Asai E et al . Clin Immunol. 2011. In Asai’s work the nucleotide mutation is referred as 2420 G>A with a E770K effect. The position of nucleotide between the two works is different, but the authors of the manuscript declare the same position for amino acid change and the same reduced recombination activity. Please, specify/insert the RS ID number of the homozygous variation. Clarification 2: In the original publication by Asai et al. 2011, the nucleotide position is mentioned as c.2420G>A. While the position of amino acid is clear from the publication, we are not sure if nucleotide position denotes the position in cDNA or other. In our case, we mentioned the cDNA change as c.2308G>A and amino acid change as p.E770K. We clearly indicated the change in cDNA and it is also the reported nomenclature from database. For reference, Cosmic mutation ID: COSM3447065. The rsID for mutation is rs768260595. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Itliani P. Peer Review Report For: Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency [version 2; peer review: 2 approved, 1 not approved] . F1000Research 2017, 5 :2532 ( https://doi.org/10.5256/f1000research.10202.r17720) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/5-2532/v1#referee-response-17720 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Case Report: Whole exome sequencing identifies...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/5-2532/v2" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/5-2532/v2&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/5-2532/v2" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Govindaraj GM et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/5-2532/v2/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/5-2532", templates : { twitter : "Case Report: Whole exome sequencing identifies variation c.2308G>A.... Govindaraj GM et al., published by " + "@F1000Research" + ", https://f1000research.com/articles/5-2532/v2" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/9473/13267") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "13267"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "17536": 0, "17537": 0, "17538": 0, "17539": 0, "20355": 41, "19044": 0, "19588": 36, "19589": 0, "19045": 0, "19046": 0, "17193": 0, "26544": 13, "17072": 0, "26545": 0, "17073": 0, "26546": 21, "17074": 0, "17075": 0, "19607": 0, "19608": 0, "17720": 36, "19609": 0, "19610": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "131e23ab-09df-4c86-92f0-c01862b7ff96"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });